188 related articles for article (PubMed ID: 15215225)
21. Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B.
Atkinson BA; Bocanegra R; Colombo AL; Graybill JR
Antimicrob Agents Chemother; 1994 Jul; 38(7):1604-7. PubMed ID: 7979293
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata.
Mariné M; Espada R; Torrado J; Pastor FJ; Guarro J
J Antimicrob Chemother; 2008 Apr; 61(4):880-3. PubMed ID: 18256113
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
24. In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.
Sandoval-Denis M; Pastor FJ; Capilla J; Sutton DA; Fothergill AW; Guarro J
Int J Antimicrob Agents; 2014 Feb; 43(2):161-4. PubMed ID: 24360922
[TBL] [Abstract][Full Text] [Related]
25. Caspofungin: new indication. No progress in invasive candidiasis.
Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
[TBL] [Abstract][Full Text] [Related]
26. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse.
Bannatyne RM; Cheng PC; Fong IW
Infection; 1992; 20(3):168-70. PubMed ID: 1644494
[TBL] [Abstract][Full Text] [Related]
28. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
29. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
30. Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus.
Rodríguez MM; Pastor FJ; Serena C; Guarro J
J Antimicrob Chemother; 2009 Feb; 63(2):361-4. PubMed ID: 19054804
[TBL] [Abstract][Full Text] [Related]
31. Voriconazole for candidosis: an important addition?
Graybill JR
Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
[No Abstract] [Full Text] [Related]
32. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of voriconazole in a murine model of invasive paecilomycosis.
Rodríguez MM; Pastor FJ; Serena C; Guarro J
Int J Antimicrob Agents; 2010 Apr; 35(4):362-5. PubMed ID: 20129763
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.
Szilágyi J; Földi R; Gesztelyi R; Bayegan S; Kardos G; Juhász B; Majoros L
Chemotherapy; 2012; 58(2):159-64. PubMed ID: 22626860
[TBL] [Abstract][Full Text] [Related]
35. SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
Karyotakis NC; Dignani MC; Anaissie EJ
Antimicrob Agents Chemother; 1995 Mar; 39(3):775-7. PubMed ID: 7793892
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis.
Serena C; Gilgado F; Mariné M; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2006 Jun; 50(6):2240-3. PubMed ID: 16723595
[TBL] [Abstract][Full Text] [Related]
37. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
Van t Wout JW; Mattie H; van Furth R
Antimicrob Agents Chemother; 1989 Feb; 33(2):147-51. PubMed ID: 2541654
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
[TBL] [Abstract][Full Text] [Related]
40. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
